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Methods: This was a prospective observational study carried out at
a single tertiary care centre of north India. Sequential patients who
presented with STEMI and at least 1 or more lesions ≥70% in a
major epicardial vessel other than the infarct-related artery
were included. Patients who underwent primary PCI or PCI after
thrombolysis were included. Patients were assigned to 3 different
strategies: culprit vessel angioplasty-only (COR); staged revascu-
larization (SR); and simultaneous treatment of non-IRA (CR).
Results: A total of 109 patients of acute ST elevation MI were
enrolled during a period of 6 months. The mean age was 55.38
 10.0 years, 84 (77.0%) weremen. The COR group included 48 (44%)
patients, the SR group 44 (40%) and the CR group 17 (16%). The
elective PCI in the SR group was performed on average 58  20days
after the initial PCI. After a mean follow-up of 6 months, 9 (8%)
patients died, 3 (2.6%) from cardiac causes. Throughout the follow-
up, 32 (30%) patients experienced at least 1 MACE, 14 (45.0%) in the
COR group, 8 (25.0%) in the SR group and 10 (30%) in the CR group,
p < 0.001. The incidence of inhospital death, repeat revasculariza-
tion and re-hospitalization was signiﬁcantly higher in the COR
group (all p < 0.05), whereas there was no signiﬁcant difference in
re-infarction among the 3 groups. A total of 2 patients (1 each in the
SR and CR group) received both a re-PCI and a subsequent CABG.
Survival free of re-PCI was worse in the COR group compared with
both the CR ( p < 0.001) and the SR group ( p < 0.005), whereas it was
similar between the CR and SR groups ( p < 0.467). Mortality was
more frequent in the COR group although it did not reach statistical
signiﬁcance. The COR group showed a tendency for a worse overall
survival compared with the other groups, without reaching statis-
tical signiﬁcance ( p < 0.151).
Conclusion: Culprit vessel-only PCI was associated with highest
rate of long-term MACE compared with multivessel treatment.
Patients scheduled for staged revascularization experienced a
similar rate of MACE to patients undergoing simultaneous treat-
ment of non-IRA.
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Intra aortic balloon pump (IABP) is an important short term LV
mechanical assist device in patientswith acute LVdysfunction and
cardiogenic shock of varying etiology like acute MI, acute myocar-
ditis, acute valvular regurgitation secondary to infective endiocar-
ditis etc. Recently published 1ABP-SHOCK II trial showed that IABP
in acute MI setting in Intensive Coronary Care Unit (ICCU) does not
have any mortality advantage. In this study, we have studied the
outcome of patients who underwent IABP insertions in our hospi-
tal due to various indications.
Aims and objective: To study the outcome of patients who under-
went IABP insertion in ICCU settings.
Material and methods: We retrospectively analyzed the data of
patients who received IABP insertion in our ICCU due to various
indications during January 2014–December 2014. We studied the
clinical details, indications of IABP insertion, complications and
their outcome. The outcome was noted in terms of all cause
mortality in ICCU, all causemortality during or after surgery during
index hospitalization and survival till discharge.
Results: During the above mentioned period, 35 patients under-
went IABP insertion out of which 26 (74.29%) were male, and
9 (25.71%) were females. Mean age of study population was 56
years. 33 (94.29%) patients came with acute STEMI, 1 (2.86%) had
myocarditis and 1 (2.86%) patient had acute severe MR secondary
to infective endocarditis. Out of 33 patients with STEMI, 17 (51.52%)
patients had cardiogenic shock due to pump failure, 6 (18.19%)
patients had post MI acute VSD, 4 (12.12%) patients had acute
ischemic severe MR, 2 (6.06%) patients had refractory ventricular
arrhythmias and 4 (12.12%) patients had refractory angina despite
full medical antianginal support.
17 (51.52%) patients had altered renal function in terms of
increased blood urea and serum creatinine before IABP insertion.
Average duration of IABP insertion was 2.3  1.2 days. During IABP
insertion, 9 (52.94%) patients developed leucocytosis, 3 (17.65%)
patients had anemia (1 required blood transfusion), 3 (17.65%)
patients had thrombocytopenia. Out of 17 patients who had
deranged renal function, 13 (76.47%) patients continued to have
renal dysfunction and 4 (23.53%) patients improved. However, 8
(47%) patients developed new onset renal dysfunction on IABP. 8
(22.86%) patients on IABP developed puncture site complications (3
had hematoma, 2 had limb ischemia and 3 had CVA). However
except for one patient with hematoma who required BT, all others
were managed conservatively. Out of 35 patients, 20 (57.14%)
patients died during index hospitalization (14 before surgery and
6 after surgery). 14 (40%) patients died in ICCU before they could
have been operated (pump failure-10, MI + VSD-3, MI + MR-1). One
patient of myocarditis was managed conservatively. Remaining 14
patients underwent surgery. During post surgery stay 6 (17.14%)
patients died (3 CABG patients, 2 CABG + VSD repair, ICABG
+ MVR). Out of 17 patients with deranged renal function on admis-
sion, 14 (82.35%) died.
Conclusion: Cardiogenic shock in acute MI setting continues to
have high mortality despite IABP support. Patients with impaired
renal function on admission are at particularly at higher risk for
mortality.
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Introduction: Left ventricular assist devices (LVADs) were origin-
ally developed as a temporary bridge to heart recovery and then
approved as bridge to Heart Transplant for End stage heart failure
patients falling in INTERMACS category 1, 2, and 3. Successful
outcomes with these indications justiﬁed usage of LVADs as des-
tination therapy. We report our initial experience on a series of 9
patients implanted with LVAD as destination therapy who were
either unsuitable for transplant or due to non-availability of sui-
table heart when patients were sick or as patient's choice with 4
months to 3 years follow-up.
Patient proﬁle: The hospital records of 11 patients implanted with
LVAD between Nov 2012 and Dec 2014 were retrospectively ana-
lyzed. There were 8 males and 3 females with age ranging from 26
to 51 years (mean – 47 years). 2 models of LVADs were implanted –
HEARTMATE–II (Thoratec-Axial Flow) in 3 patients and HEART-
WARE (HVAD – Centrifugal ﬂow) in 8 patients. Heart Mate 2 (infra-
diaphragmatic pocket) was chosen for body weight more than
70 kg and HEART WARE for low body weight patients (intraper-
icardial pocket, smaller device).
Basic diagnoses and clinical condition: Out of 11 patients 4 had
ischemic cardiomyopathy, one had recent anterior myocardial
infarction with recurrent VT and LV dysfunction, one had severe
valvular aortic stenosiswith severe LV dysfunction and other 3 had
dilated cardiomyopathy with severe heart failure. Other 2 patients
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had restrictive cardiomyopathy with cardiogenic shock and DCM
secondary to cobalt poisoning. Classiﬁcation of degree of heart
failure prior to LVAD was done as per INTERMACS score and 7
patients were classiﬁed at INTERMACS category 2, 3 patients in
INTERMACS category 3 and one in INTERMACS 4. 2 patients were
on prior ECMO support and 8 were on inotropes prior to LVAD
implant. 3 patients had high creatininemore than 2 and 3 had high
bilirubin and altered LIVER function. In all patients ECHO derived
RV function, RV stroke works index and pulmonary vascular resis-
tance were measures carefully. RV function parameters include
TAPSE, mean area change of RV and S' by tissue Doppler. PVR
calculated by cardiac catheterization with cardiac output mea-
sured by thermodilution catheter.
Results: 9 patients were discharged successfully from the hospital.
There was one hospital mortality due to sepsis and intracerebral
hemorrhage. And another due to severe right heart failure and liver
failure. All patients were put on oral anticoagulants (Warfarin). All
the 9 discharged patients were assessed every 2months post LVAD
with pump interrogation, echocardiography and clinician's judg-
ment of Quality of life (Minnesota QOLI) and PT/INR. All patients
reported a good to excellent improvement. 7 patients are doing
well with good pump parameters and no signs of heart failure after
a minimum of 4 months andmaximum of 3 years follow-up There
was one late mortality 18 months post LVAD due to fulminant
hepatic failure. There was no incidence of CVA or signiﬁcant aortic
leak.
Conclusion: LV assist devices can be safely implanted in terminally
ill heart failure patients. Good patient selection, adequate patient
optimization before implant and timing of intervention are the key
to successful outcomes. Meticulous assessment and management
of RV function and strict anticoagulation regimen plays a crucial
role.
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Peadatric heart transplantation poses huge challenges especially in
developing country like India. A common challenge for sick chil-
dren with severe, end stage heart failure is paucity of donors of
similar weight, because child heart donors are rare in India.
Because of this problem some of the strategies employed by
transplant teams is usage of oversized donors up to 2 times body
weight and also utilizing ABO incompatible donors. Here we report
our unique experience in 2 children aged 13 years (HK,
weight = 37 kg) and 10 years (BJ, weight = 25 kg), both of whom
needed oversized donors.
We report 2 children suffering from end stage heart failure due to
dilated cardiomyopathy. Preoperatively, they were in INTERMACS
Grade 3–4 CHF and on intermittant IV milrinone infusion. Creati-
nine levels 1.8–2 mg/dl and bilirubin levels 2 mg and 2.7 mg/dl.
Cardiac cath showed PVR of 4 and 4.2 Wood units respectively.
They were transplanted with donor hearts of 65 kg and 50 kg
respectively. On the 2–3rd postoperative day, both patients had
seizures (right focal in one and generalized in other) followed by
reduced consciousness levels. BP was noted to be persistently
above 150/90 in the ﬁrst 2 days although they were on one inotrope
(isoprenaline). The problemwas recognized as Big Heart Syndrome
and appropriate action take to reduce cerebral hyperperfusion and
reactive vasoconstriction with BP lowering using small doses of
nifedipine and NTG and slow tapering of inotrope. Both patients
recovered completely over next 8–10 days.
Big Heart Syndrome, a well described entity in countries with large
transplant programmes but not so commonly known in India. This
syndrome has been described when donor hearts are oversized.
This procedure is deemed suboptimal but becomes extremely
essential when recipient is sick because of heart failure and same
size donors are unavailable. This is a common problem in coun-
tries with Inadequate Organ Sharing and Donation programmes in
children with end stage heart failure below body weight of 35 kg.
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We studied 36 patients who underwent heart transplant in our
center between 2011 and 2014 who had elevated creatinine more
than 1. 8 mg/dl and creatinine clearance less than 40 ml/min and
who were selected for a induction therapy using modiﬁed immu-
nosuppressive regime with the CD 25 inhibitor basilixmab (simu-
lect) – different from International protocols using antithymocyte
globulin or OK T3.
Patient proﬁle – Age range 10–66 years, weight range – 34–70 kg,
creatinine range 1.8–2.6 mg/dl. All patients were NYHA class 3 and
above, 24 were in NYHA class 4 (severe CHF) and 16 were in
INTERMACS grade 3 and below.
Almost all had raised JVP with pedal edema, 20 had ascites and 26
had albumin less than 3 mg/dl.
LV EF 12–30%, 34 had moderate to severe RV dysfunction.
Cardiac cath done in all – RA mean = 18–24 mmHg, PA mean = 28–
40 mmHg PVR range = 2.1–4.5 Wood units. A total of 5 patients had
PVR more than 4 (labile with milrinone and nitric oxide).
All patients were put on IV milrinone infusion for 5–7 days before
heart transplant which reduced RA mean by average of 8 mmHg,
PVR by 2.3 WU, improved NYHA class by 1 grade and improved
urine output and Appetite. A total of 2 patients were tested with
inhaled NO with up to 18 mm fall in PA mean pressure.
Just before heart transplant, all patients received 10–20mg of basi-
liximab (dose as per bodyweight and general condition) single dose.
Post operatively in 26 patients creatinine levels normalized by day 5,
allowing initiation of tacrolimus. In other 10 patients tacrolimus
couldbestartedonlyatday10withno ill effectsor rejectionepisodes.
In all patients CD 25 level was checked on day 3 and second dose of
simulect given only of CD 25 more than 3%. Post op no patient had
sustained neutropenia. Only 2 patients needed therapy for azotemia
with post operative dialysis. A total of 1 patient died of severe RF and
sepsis. Advantages of induction therapy using basiliximab will be
discussedalongwithpathophysiologyofazotemia insevereCHFand
reversal of cardiorenal syndrome using milrinone.
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